Ignite Creation Date:
2024-05-05 @ 7:36 PM
Last Modification Date:
2024-10-26 @ 9:51 AM
Study NCT ID:
NCT00708773
Status:
COMPLETED
Last Update Posted:
2017-01-04
First Post:
2008-06-27
Brief Title:
Genotype-Directed Dose-Escalation Study of Irinotecan in Patients With Advanced Solid Tumors
Sponsor:
University of Chicago
Organization:
University of Chicago
Study Overview
Official Title:
A Phase I Genotype-Directed Dose-Escalation Study of Irinotecan NSC616348 CPT-11 Camptosar in Patients With Advanced Solid Tumors
Status:
COMPLETED
Status Verified Date:
2017-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Describe the dose-limiting toxicity DLT and maximum tolerated dose MTD of irinotecan in cancer patients with advanced solid tumors with UGT1A1 66 and 67 genotypes
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None